Making the Connection Between Patients & Providers

A Modern Approach to the Treatment of Type 1 and Type 2 Diabetes

12th Year in a Unique National Series

The University of California San Diego/Taking Control Of Your Diabetes MTC Continuing Medical Education program is offered in eight cities each year and provides an innovative and unique opportunity to bridge the gap between patient and provider education.

This conference will blow you away with the most effective cutting-edge strategies on diabetes management (yes, we are bragging a little bit but the conference is really that good). Even better, this isn't your typical sterile and boring program! We promise to infuse a little humor and interesting interaction along the way. Most importantly, you'll learn how to help your patient reach their treatment goals and avoid acute and chronic complications.

Here's how it breaks down.

This premier conference focuses on four distinct areas of diabetes management:

  • Patient adherence while avoiding clinical inertia for improved diabetes outcomes.
  • Oral agents for the treatment of type 2 diabetes and their effect on cardiovascular health.
  • Injectable therapies for use in patients with type 2 diabetes.
  • Cutting-edge strategies for patients with type 1 diabetes.

In addition, this course is held in tandem with a separate, large-scale patient-focused conference. This will give the opportunity to observe and interact with people who have diabetes and are engaged in their own intensive educational environment. By making that connection with patients, providers will acquire new skills and insight into what empowers patients with diabetes to develop healthy self-management of their condition.

Watch the video to discover the benefits of attending our medical educational program...

Acknowledgment of Commercial Support

  • This activity is supported by educational grants from: Abbot Diabetes Care Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC, Dexcom, Intarcia, Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, Lilly USA LLC, Merck, and NovoNordisk.